EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Stephen Ahenkorah, Anjong Florence Tikum, Emmanuel Nwangele, Nikita Henning, Frederik Cleeren, Humphrey Fonge iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024-06 · 51 (7) · 2070-2084

DOI: 10.1007/s00259-024-06648-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 20.02.2024. Verfasst von Jessica Pougoue Ketchemen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Copper Radioisotopes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Institute of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesCopper RadioisotopesAnimalsHumansMiceFemaleCell Line, TumorTissue DistributionTheranostic NanomedicineRadiopharmaceuticalsImmunoconjugates

Stichwörter der Autor:innen

67Cup-SCN-Bn-NOTADosimetryHER2-positive breast cancerTheranostics

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCopper RadioisotopesRadiopharmaceuticalsImmunoconjugatesERBB2 protein, humanCopper-67

Autor:innen und Institutionen

  • Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
  • Department of Pathology and Lab. Medicine, College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5A2, Canada.
  • NURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.
  • Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium.
  • Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. humphrey.fonge@usask.ca.
  • Department of Medical Imaging, Royal University Hospital Saskatoon, Saskatoon, SK, S7N 0W8, Canada. humphrey.fonge@usask.ca.

ORCID-Profile: Humphrey Fonge

Förderung

  • Institute of Cancer Research

Zitieren

APA

Pougoue Ketchemen, J., Njotu, F. N., Babeker, H., Ahenkorah, S., Tikum, A. F., Nwangele, E., Henning, N., Cleeren, F., & Fonge, H. (2024). Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 51(7), 2070-2084. https://doi.org/10.1007/s00259-024-06648-3

Vancouver

Pougoue Ketchemen J, Njotu FN, Babeker H, Ahenkorah S, Tikum AF, Nwangele E, et al. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(7):2070-2084. doi:10.1007/s00259-024-06648-3

BibTeX
@article{PougoueKetchemen2024,
  author = {Pougoue Ketchemen, Jessica and Njotu, Fabrice Ngoh and Babeker, Hanan and Ahenkorah, Stephen and Tikum, Anjong Florence and Nwangele, Emmanuel and Henning, Nikita and Cleeren, Frederik and Fonge, Humphrey},
  title = {Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {7},
  pages = {2070--2084},
  doi = {10.1007/s00259-024-06648-3}
}
Kostenlos starten →